文献速递免疫规划传染病防控与疫情报告

改良安卡拉痘苗疫苗三种免疫程序和两种接种方式的安全性和免疫原性:一项随机临床非劣效性试验

Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
PubMed 文献 · Vaccine · 2017-02-27

为指导天花病毒释放时改良安卡拉痘苗(MVA)疫苗的使用,该随机临床非劣效性试验在18-40岁健康成人中比较了缩短接种间隔(第1和15天、第1和22天)及喷射注射器(JI)接种与标准程序(第1和29天皮下注射针筒)的免疫原性和安全性。结果显示,三种非标准方案均未在PRNT抗体应答上达到非劣效性;第1和22天压缩程序及JI接种在ELISA抗体应答上达到非劣效性。JI接种局部反应如发红和肿胀报告更常见,观察到4例接种后过敏反应。

要点

  • 三种非标准方案(第1和15天、第1和22天、JI第1和29天)在PRNT抗体应答上均未达到非劣效性。
  • 第1和22天压缩程序及JI接种在第1和29天标准程序下ELISA抗体应答达到非劣效性。
  • JI接种的局部反应(发红、肿胀)报告更常见,观察到4例接种后过敏反应。

核心结论

  • PRNT抗体应答的主要终点评估不支持通过皮下注射针筒采用压缩程序或通过JI在标准程序下接种MVA疫苗的替代策略。

研究设计与样本

  • 随机临床非劣效性试验,纳入18-40岁健康成人,随机分配至第1和29天皮下注射针筒接种(标准)、第1和15天、第1和22天或第1和29天JI皮下接种MVA疫苗。
  • 第二次接种后四个时间点采血,采用PRNT(主要终点)和ELISA(次要终点)抗体检测,以第二次接种后所有可用测量中的最高滴度定义为峰值滴度。
  • 非劣效性判定标准:标准组与非标准组平均log2峰值滴度差异的98.33%置信区间上限小于1。

主要发现

  • PRNT抗体应答:三种非标准研究组均未建立非劣效性。
  • ELISA抗体应答:第1和22天压缩程序及JI接种建立非劣效性。
  • JI接种的局部反应(如发红和肿胀)报告更常见。
  • 观察到4例接种后过敏反应。

关键数值与推荐

  • 非劣效性界值:标准组与非标准组平均log2峰值滴度差异的98.33%置信区间上限小于1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To guide the use of modified vaccinia Ankara (MVA) vaccine in response to a release of smallpox virus, the immunogenicity and safety of shorter vaccination intervals, and administration by jet injector (JI), were compared to the standard schedule of administration on Days 1 and 29 by syringe and needle (S&N). METHODS: Healthy adults 18-40years of age were randomly assigned to receive MVA vaccine subcutaneously by S&N on Days 1 and 29 (standard), Days 1 and 15, or Days 1 and 22, or to receive the vaccine subcutaneously by JI on Days 1 and 29. Blood was collected at four time points after the second vaccination for plaque reduction neutralization test (PRNT) (primary endpoint) and ELISA (secondary endpoint) antibody assays. For each subject, the peak PRNT (or ELISA) titer was defined by the highest PRNT (or ELISA) titer among all available measurements post second vaccination. Non-inferiority of a non-standard arm compared to the standard arm was met if the upper limit of the 98.33% confidence interval of the difference in the mean log2 peak titers between the standard and non-standard arm was less than 1. RESULTS: Non-inferiority of the PRNT antibody response was not established for any of the three non-standard study arms. Non-inferiority of the ELISA antibody response was established for the Day 1 and 22 compressed schedule and for administration by JI. Solicited local reactions, such as redness and swelling, tended to be more commonly reported with JI administration. Four post-vaccination hypersensitivity reactions were observed. CONCLUSIONS: Evaluations of the primary endpoint of PRNT antibody responses do not support alternative strategies of administering MVA vaccine by S&N on compressed schedules or administration by JI on the standard schedule. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01827371.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jackson LA, Frey SE, El Sahly HM, et al. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017. PMID: 28256358. doi:10.1016/j.vaccine.2017.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。